Clinical trial
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or…
NCT00253370 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00253370 |
|---|---|
| Title | Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer |
| Official title | A Phase II Study to Evaluate Overall Response Rate of BAY 43-9006 (Sorafenib) Combined With Docetaxel and Cisplatin or Oxaliplatin in the Treatment of Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer |
| Intervention type | Drug |
| Interventions | BAY 43-9006, docetaxel, cisplatin |
| Enrollment | 44 |
| Start date | Oct 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | Sep 1, 2010 |
| First posted | Nov 15, 2005 |
| Last update posted | Nov 24, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: